Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of cnidium lactone and trastuzumab combined for preparing medicine for treating gastric cancer

A kind of osthole, combined preparation technology, applied in the field of medicine

Active Publication Date: 2018-07-27
河南普诺易生物制品研究院有限公司 +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the combination of osthole and trastuzumab in the treatment of gastric cancer with high expression of HER2 has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cnidium lactone and trastuzumab combined for preparing medicine for treating gastric cancer
  • Application of cnidium lactone and trastuzumab combined for preparing medicine for treating gastric cancer
  • Application of cnidium lactone and trastuzumab combined for preparing medicine for treating gastric cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 The combination of osthole and trastuzumab has an in vitro inhibitory effect on gastric cancer N87 cells

[0027] Take N87 cells in good growth state, and use 1.5×10 cells per well 3 Spread evenly in 96-well cell culture plate, in the well cell culture plate, 37 ℃, 8% CO 2 Cultivate in the incubator for 24 hours; set trastuzumab monotherapy group, osthole monotherapy group and osthole combined trastuzumab group. Add trastuzumab (Tra, Trastuzumab) serially diluted from 50 μg / mL to each well, and repeat three times; add osthole (Ost, Osthole) serially diluted from 100 μM to each well; wait for drug treatment for 48 h After that, add CCK-8 reagent to develop color. The cell viability was calculated by reading the value at a wavelength of 450 nm on an iMark microplate reader.

[0028] Cell viability (%)=[(absorbance value of test group-absorbance value of blank group) / (absorbance value of control group-absorbance value of blank group)]×100

[0029] Experimenta...

Embodiment 2

[0033] Example 2 Combination of osthole and trastuzumab promotes apoptosis of N87 cells

[0034] Take N87 cells in good growth state to 5×10 6 / / well spread evenly in a 6-well plate. The cells in each well were subjected to the following four treatments: ① IgG (Control) (10 μg / mL); ② 10 μg / mL trastuzumab; ③ 40 μM osthole; ④ 10 μg / mL trastuzumab + 40 μM Osthole; the treatment condition is 37°C 8% CO 2 Incubate for 30 hours. Then stained with Annexin V and propidium iodide (PI), and the proportion of apoptotic cells was determined by flow cytometry.

[0035] Experimental results such as Figure 4 with Figure 5 as shown, Figure 4 is the N87 cell apoptosis level measurement chart, Figure 5 It is the proportion analysis chart of N87 cell apoptosis. The proportion of apoptotic cells in the combination group of trastuzumab and osthole was significantly higher than that in the group of trastuzumab alone or osthole alone. Therefore, the increase in the proportion of cell ap...

Embodiment 3

[0036] Example 3 Osthole and trastuzumab combined for inhibiting tumor cell growth in vivo

[0037] Female NOD-SCID mice were subcutaneously inoculated with gastric cancer N87 cells, and the tumor tissue reached 80 mm after inoculation of tumor cells. 3 -120mm 3 Size, intravenous injection of the following 4 groups of mice, 6 mice in each group: ① Human IgG (Control) (15 mg / kg); ② Trastuzumab (Trastuzumab) (15 mg / kg); ③ Osthole group (Osthole) (100 mg / kg); ④ Trastuzumab (15 mg / kg) + osthole (100 mg / kg) group (Trastuzumab + Osthole). The administration method of osthole was intraperitoneal administration every day, and the administration method of trastuzumab was once every three days for a total of 2 weeks. During the administration process, the tumor growth was observed every 2 days, and the tumor size and weight were measured to evaluate the antitumor effect of the drug. Experimental results such as Image 6 with Figure 7 shown. Image 6 The middle ordinate is the tum...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of cnidium lactone and trastuzumab combined for preparing a medicine for treating a gastric cancer. In the application, the cnidium lactone and the trastuzumab are firstly combined for treating the gastric cancer, especially a HER2 high-expression gastric cancer. Proved by an in-vitro test, the combined treatment of the cnidium lactone and the trastuzumab shows a strong tumor suppressing effect to HER2 high-expression gastric cancer N87 cells, the treatment effect of the combined treatment exceeds an exclusive use treatment group of the cnidium lactone ora trastuzumab monoclonal antibody, and the synergistic inhibition effect is shown. Proved by the in-vitro test, the administration of the trastuzumab monoclonal antibody combined with the cnidium lactone, compared with the independent administration of the cnidium lactone or the trastuzumab monoclonal antibody, shows the more effective tumor inhibition development effect in an HER2 high-expressiongastric cancer N87 tumor-bearing mice model.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of osthole and trastuzumab in the joint preparation of a drug for treating gastric cancer. Background technique [0002] Malignant tumor is a disease that seriously endangers human health, ranking second among various fatal diseases. In recent years, the incidence of malignant tumors has increased significantly. At the same time, its treatment effect is poor, and it is prone to metastasis in the late stage, and the prognosis is poor. At present, conventional treatment methods such as radiotherapy, chemotherapy and surgery have relieved the pain to a great extent, but the side effects and limitations of these treatments are still very large, and it is difficult to further improve the curative effect. [0003] Proliferation of normal cells is strictly controlled by activation of their growth factor receptors, such as growth factor receptor tyrosine kinases, by t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K31/37A61P35/00
CPCA61K31/37A61K39/3955A61P35/00A61K2300/00
Inventor 杨赟董卫华赵孝亮
Owner 河南普诺易生物制品研究院有限公司